IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$7.58
Market Cap
$8.03B
52W High
$9.60
52W Low
$6.65
ADV30
8,409,627
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 51,240,000 | 50,942,000 | -61,697,000 | -230,378,000 | 628,504,000 | 75,670,000 | 1,674,265,000 |
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
| Sep 2025 | 32,061,000 | 31,884,000 | -55,630,000 | -67,253,000 | 518,987,000 | 60,241,000 | 1,042,397,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-281,138,000
Investing CF
$-276,907,000
Financing CF
$496,782,000
CapEx
$-7,376,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.97
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,589,806,000
Inventory
$1,940,000
Receivables
$53,499,000
ST Investments
$281,701,000
EBIT TTM
$-878,096,000
Pretax Income TTM
$-992,580,000
Interest Exp TTM
$114,484,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$165,792,000
EBITDA
$-235,298,000
Free Cash Flow
$-186,564,128
Enterprise Value
$8,905,456,640
Total Cash
$357,371,008
Total Debt
$1,228,401,024
Shares Out
1,059,836,273
Trailing EPS
$-0.92
Book Value
$-0.99
ROE
—
ROA
-30.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | — | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | — | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | — | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | — | -337,509,000 |
TTM Snapshot
Revenues TTM
$6,372,000
NetIncome TTM
$-379,878,000
OpCashFlow TTM
$0
Assets (Latest)
$382,933,000
Forward EPS
$-0.13
Max Pain — expiry 2026-08-28
max pain strike: $6.00 · spot: $7.99 · call oi: 9,322 · put oi: 2,433
Expected Move to 2026-08-28:
±$0.42
(5.32%) —
implied range
$7.56 –
$8.41
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | $8.38B | $134.79 | — |
| QGEN | QIAGEN N.V. | $8.63B | $41.78 | — |
| TWST | Twist Bioscience Corp | $8.83B | $140.80 | — |
| IMVT | Immunovant, Inc. | $8.95B | $43.32 | — |
| SRRK | Scholar Rock Holding Corp | $7.09B | $58.20 | — |
News headlines (Yahoo Finance, 1h cache)
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom
2026-08-17 05:17 · Yahoo
SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight
2026-08-14 02:24 · Yahoo
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns
2026-08-07 08:14 · Yahoo
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses
2026-08-07 06:14 · Yahoo
Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive
2026-08-05 05:17 · Yahoo
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales
2026-08-04 13:25 · Yahoo
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
2026-08-04 12:50 · Yahoo
IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback
2026-08-03 23:47 · Yahoo
ImmunityBio (IBRX) Could Be 41% Undervalued On Anktiva Optimism
2026-07-16 21:12 · Yahoo
Is ImmunityBio (IBRX) Reasonably Valued After Its 283% Rally?
2026-07-16 16:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.